Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Tuberculosis treatment in the private healthcare sector in India: an analysis of recent trends and volumes using drug sales data.

Arinaminpathy N, Batra D, Maheshwari N, Swaroop K, Sharma L, Sachdeva KS, Khaparde S, Rao R, Gupta D, Vadera B, Nair SA, Rade K, Kumta S, Dewan P.

BMC Infect Dis. 2019 Jun 19;19(1):539. doi: 10.1186/s12879-019-4169-y.

2.

Size and usage patterns of private TB drug markets in the high burden countries.

Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME.

PLoS One. 2011 May 4;6(5):e18964. doi: 10.1371/journal.pone.0018964.

3.

The number of privately treated tuberculosis cases in India: an estimation from drug sales data.

Arinaminpathy N, Batra D, Khaparde S, Vualnam T, Maheshwari N, Sharma L, Nair SA, Dewan P.

Lancet Infect Dis. 2016 Nov;16(11):1255-1260. doi: 10.1016/S1473-3099(16)30259-6. Epub 2016 Aug 25.

4.

Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis.

Nair SA, Raizada N, Sachdeva KS, Denkinger C, Schumacher S, Dewan P, Kulsange S, Boehme C, Paramsivan CN, Arinaminpathy N.

PLoS One. 2016 Feb 26;11(2):e0150054. doi: 10.1371/journal.pone.0150054. eCollection 2016.

5.

The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis.

Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE, Chadha VK, Rade K, Swaminathan S, Mayer KH.

PLoS Med. 2016 Oct 25;13(10):e1002149. doi: 10.1371/journal.pmed.1002149. eCollection 2016 Oct. Review.

6.

Role of the private sector in vaccination service delivery in India: evidence from private-sector vaccine sales data, 2009-12.

Sharma A, Kaplan WA, Chokshi M, Zodpey SP.

Health Policy Plan. 2016 Sep;31(7):884-96. doi: 10.1093/heapol/czw008. Epub 2016 Mar 14.

PMID:
26976803
7.

Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities.

Kwan A, Daniels B, Saria V, Satyanarayana S, Subbaraman R, McDowell A, Bergkvist S, Das RK, Das V, Das J, Pai M.

PLoS Med. 2018 Sep 25;15(9):e1002653. doi: 10.1371/journal.pmed.1002653. eCollection 2018 Sep.

8.

Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.

Catalani E.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S289-91; discussion S317-21.

PMID:
10593707
9.

Estimate of the global market for rifampicin-containing fixed-dose combination tablets.

Norval PY, Blomberg B, Kitler ME, Dye C, Spinaci S.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S292-300; discussion S317-21.

PMID:
10593708
10.

Tuberculosis control and the private health sector in Bolivia: a survey of pharmacies.

Lambert ML, Delgado R, Michaux G, Volz A, Van der Stuyft P.

Int J Tuberc Lung Dis. 2004 Nov;8(11):1325-9.

PMID:
15581200
11.

Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.

Chatla C, Jaju J, Achanta S, Samyuktha R, Chakramahanti S, Purad C, Chepuri R, Nair SA, Parmar M.

Indian J Tuberc. 2018 Jul;65(3):218-224. doi: 10.1016/j.ijtb.2018.02.004. Epub 2018 Feb 11.

PMID:
29933863
12.

Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?

Udwadia ZF, Pinto LM, Uplekar MW.

PLoS One. 2010 Aug 9;5(8):e12023. doi: 10.1371/journal.pone.0012023.

13.

Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.

Khaparde S, Raizada N, Nair SA, Denkinger C, Sachdeva KS, Paramasivan CN, Salhotra VS, Vassall A, Hoog AV.

PLoS One. 2017 Sep 7;12(9):e0184270. doi: 10.1371/journal.pone.0184270. eCollection 2017.

14.

Accelerating TB notification from the private health sector in Delhi, India.

Kundu D, Chopra K, Khanna A, Babbar N, Padmini TJ.

Indian J Tuberc. 2016 Jan;63(1):8-12. doi: 10.1016/j.ijtb.2016.02.002. Epub 2016 Apr 29.

PMID:
27235938
15.

Tuberculosis patients not covered by treatment in public health services: findings from India's National Family Health Survey 2015-16.

Pardeshi G, Deluca A, Agarwal S, Kishore J.

Trop Med Int Health. 2018 Aug;23(8):886-895. doi: 10.1111/tmi.13086. Epub 2018 Jun 25.

16.

Patients pathways to tuberculosis diagnosis and treatment in a fragmented health system: a qualitative study from a south Indian district.

Yellappa V, Lefèvre P, Battaglioli T, Devadasan N, Van der Stuyft P.

BMC Public Health. 2017 Aug 4;17(1):635. doi: 10.1186/s12889-017-4627-7.

17.

Assessment of doctors' knowledge regarding tuberculosis management in Lucknow, India: a public-private sector comparison.

Vandan N, Ali M, Prasad R, Kuroiwa C.

Public Health. 2009 Jul;123(7):484-9. doi: 10.1016/j.puhe.2009.05.004. Epub 2009 Jun 26.

PMID:
19560176
18.

Successfully Engaging Private Providers to Improve Diagnosis, Notification, and Treatment of TB and Drug-Resistant TB: The EQUIP Public-Private Model in Chennai, India.

Ananthakrishnan R, Richardson MD, van den Hof S, Rangaswamy R, Thiagesan R, Auguesteen S, Kamp N.

Glob Health Sci Pract. 2019 Mar 29;7(1):41-53. doi: 10.9745/GHSP-D-18-00318. Print 2019 Mar 22.

19.

Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis.

Jarosławski S, Pai M.

J Epidemiol Glob Health. 2012 Mar;2(1):39-50. doi: 10.1016/j.jegh.2011.12.001. Epub 2012 Feb 1. Review.

20.

Market size and sales pattern of tuberculosis drugs in the Philippines.

Islam T, van Weezenbeek C, Vianzon R, Garfin AM, Hiatt T, Lew WJ, Tisocki K.

Public Health Action. 2013 Dec 21;3(4):337-41. doi: 10.5588/pha.13.0094.

Supplemental Content

Support Center